Researchers launch the first-in-human phase 1 clinical trial to assess the safety and efficacy of a gene therapy which will deliver BDNF to the brains of those with Alzheimer’s and mild cognitive impairment.
Researchers launch the first-in-human phase 1 clinical trial to assess the safety and efficacy of a gene therapy which will deliver BDNF to the brains of those with Alzheimer’s and mild cognitive impairment.